Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial

Basit Öğe Kaydı
dc.contributor.authorBiteker, Murat
dc.contributor.authorEkşi Duran, Nilüfer
dc.contributor.authorKaya, Hasan
dc.contributor.authorGündüz, Sabahattin
dc.contributor.authorTanboğa, Halil İbrahim
dc.contributor.authorGökdeniz, Tayyar
dc.contributor.authorKahveci, Gökhan
dc.contributor.authorAkgün, Taylan
dc.contributor.authorYıldız, Mustafa
dc.contributor.authorÖzkan, Mehmet
dc.date.accessioned2024-07-12T21:11:01Z
dc.date.available2024-07-12T21:11:01Z
dc.date.issued2011en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractBackground Levosimendan is a promising new inodilator agent but its effectiveness in peripartum cardiomyopathy (PPCM) has not been tested in a clinical trial. The authors sought to evaluate the effect of levosimendan therapy and to determine the predictors of clinical outcome in patients with PPCM. Methods and results The authors prospectively randomized 24 consecutive women with PPCM. Twelve patients (control group) were randomized to conventional heart failure therapy and 12 patients (levosimendan group) were randomized to levosimendan in addition to the conventional therapy. Mean follow-up period was 20.9 ± 9 months (ranged 12–38 months). The two groups did not differ in baseline demographic and echocardiographic characteristics. Eleven patients (45.8%) recovered completely (6 in control group and 5 in levosimendan group, p[0.05), 6 died (25%) (3 in control group and 3 in levosimendan group), and 7 (29.1%) were left with persistent left ventricular dysfunction (PLVD) (3 in control group and 4 in levosimendan group, p[0.05). There were significant differences in baseline characteristics between deceased patients and survivors including left ventricular end-diastolic diameter (7.1 ± 0.6 vs. 6.4 ± 0.5 cm, p = 0.031), left ventricular end-systolic diameter (LVESD) (6.4 ± 0.8 vs. 5.5 ± 0.6 cm, p = 0.027), left ventricular ejection fraction (LVEF) (19.7 vs. 27.4%, p = 0.025), and left atrial diameter (4.9 ± 0.3 vs. 4.3 ± 0.4 cm, p = 0.011). Conclusions Addition of levosimendan to conventional therapy did not improve outcome in patients with PPCM. In patients with PLVD or patients who died, LVEF, LVESD and left atrial diameter were worse than those with complete resolution.en_US
dc.identifier.citationBiteker, M., Duran, N. E., Kaya, H., Gündüz, S., Tanboğa, H. İ., Gökdeniz, T., Kahveci, G., Akgün, T., Yıldız, M. ve Özkan, M. (2011). Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Randomized Controlled Trial. 100(7), s. 571-577.en_US
dc.identifier.endpage577en_US
dc.identifier.issn1861-0692
dc.identifier.issue7en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage571en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/4315
dc.identifier.volume100en_US
dc.institutionauthorEkşi Duran, Nilüfer
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofRandomized Controlled Trialen_US
dc.relation.isversionof10.1007/s00392-010-0279-7en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY03332
dc.subjectLevosimendanen_US
dc.subjectPeripartumen_US
dc.subjectCardiomyopathyen_US
dc.subjectTreatmenten_US
dc.titleEffect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trialen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu